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Maximizing positive outcomes and advancing the standard of
care for patients require that therapeutic strategies address
the changing epidemiology of infections. In addition to using
data from registered clinical trials, assessing the clinical expe-
rience with newer agents will facilitate a fuller understanding
of their potential to address changing clinical needs.
Nosocomial infections continue to impose a signiﬁcant
burden on healthcare systems globally, and the proportion of
these infections caused by Gram-positive infections is
increasing [1]. Methicillin-resistant Staphylococcus aureus
(MRSA) is of particular concern. The most recent European
Antimicrobial Resistance Surveillance System annual report
indicated that, whereas the prevalence of MRSA is decreasing
in a few countries as a result of concerted infection control
efforts, rates in many more countries, including low-endemic-
ity, medium-endemicity and high-endemicity countries, are
still increasing [2]. Almost half of all European countries in
2006 reported MRSA rates greater than 25% [2].
Of further concern is the emergence of community-asso-
ciated MRSA strains in Europe, with an epidemiology, geno-
type and resistance phenotype distinct from those of
hospital-associated MRSA strains [3]. Community-associated
MRSA clones that combine resistance with virulence, such as
the hypervirulent strain USA300, are beginning to displace
endemic hospital-associated MRSA strains in the US health-
care setting [4–6]; this is a trend that may also be seen in
Europe in the near future.
Extensive vancomycin use in treating MRSA infections,
combined with potential underdosing, has, perhaps, led in
recent years to the emergence of S. aureus strains with
reduced vancomycin susceptibility. Vancomycin-intermediate
S. aureus and heteroresistant vancomycin-intermediate
S. aureus were ﬁrst reported in the late 1990s [7,8]. To date,
several vancomycin-resistant S. aureus isolates have been
reported, mostly in the USA [9]. In addition, the phenome-
non of ‘MIC creep’—incremental increases in MICs of sus-
ceptible strains over time—has been noted for vancomycin
in several individual institutions [10–13].
Numerous studies have documented poorer outcomes
with vancomycin therapy for MRSA infection in patients
infected with strains with vancomycin MICs ‡1 mg/L and
£2 mg/L than for those infected with strains with lower
MICs [14–19]. However, patients with high vancomycin MIC
(‡1.5 mg/L) MRSA strains are more likely to have received
prior recent vancomycin treatment or to have been resi-
dents in an intensive-care unit [20,21], and these factors may
have inﬂuenced treatment outcomes. For example, if a
patient requires vancomycin therapy only a short time after
a previous course of treatment, this suggests that the original
course of vancomycin may not have fully resolved the initial
infection, and vancomycin is therefore more likely to fail
again. Additionally, the severity of illness in intensive-care
unit patients may increase the probability of treatment fail-
ure. However, a recent study has shown that a higher vanco-
mycin MIC is associated with treatment failure, irrespective
of patient baseline characteristics [22]. A 2.4-fold increase in
the rate of treatment failure was demonstrated in bacterae-
mic patients with vancomycin MICs for MRSA ‡1.5 mg/L as
compared with MICs for MRSA <1.5 mg/L; after controlling
for potential confounding variables, a high vancomycin MIC
remained a robust predictor of treatment failure.
There has been a substantial increase in the number of
strains of vancomycin-resistant enterococci in Europe, with
the global spread of clonal complex 17 causing outbreaks in
a large number of hospitals [23]. Notably, there was a rapid
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escalation in the incidence of vancomycin resistance among
European bloodstream isolates of Enterococcus faecium (from
c. 0% to c. 18%) in the SENTRY programme over the period
1999–2005 [24]. According to the European Antimicrobial
Resistance Surveillance System 2006 annual report, the coun-
tries with the most rapid increases between 2001 and 2006
were Greece (from 15% to 42%), Ireland (from 12% to 36%)
and Israel (from 14% to 28%) [2].
The changing epidemiology of Gram-positive infections in
Europe necessitates the implementation of appropriate treat-
ment strategies to maximize patient outcomes. Appropriate
initial antibiotic therapy is a vital part of such a strategy.
However, the growing rates of antibiotic resistance, coupled
with an increasing number of available antimicrobial agents,
mean that selecting an appropriate antibiotic therapy is
becoming a more complex process.
The ideal antibiotic agent should be safe and effective in a
variety of clinical situations, including infection by different
pathogens at various body sites, as well as the treatment of vul-
nerable patients with co-morbidities. There is a particular need
for agents that are effective empirically against S. aureus, regard-
less of susceptibility to penicillins, b-lactams or vancomycin.
Daptomycin (Cubicin) is the ﬁrst of a new class of cyclic
lipopeptide membrane-depolarizing antibiotics with a broad
spectrum of activity against Gram-positive bacteria, including
MRSA, vancomycin-resistant S. aureus, vancomycin-intermedi-
ate S. aureus and vancomycin-resistant enterococci [25].
With good efﬁcacy against methicillin-susceptible S. aureus
and MRSA, and good tolerability, having been noted in
phase III trials in complicated skin and soft tissue infections
(cSSTIs), bacteraemia and right-sided infective endocarditis,
daptomycin is suitable for the empirical treatment of
S. aureus infections [26,27].
Additionally, daptomycin may be an effective alternative to
vancomycin for treating MRSA bacteraemia and endocarditis.
In treating experimental endocarditis caused by MRSA strains
with a vancomycin MIC of 2 mg/L, daptomycin was signiﬁcantly
more effective than vancomycin at recommended doses [28].
Furthermore, daptomycin showed a trend towards higher
overall success as compared with vancomycin in a subanalysis
of MRSA patients enrolled in the phase III trial of S. aureus
bacteraemia and endocarditis [29]. The overall success rate
was 44% (20/45) for daptomycin-treated patients, as compared
with 32% (14/43) for patients treated with a vancomycin–
gentamicin combination (difference 11.9%; CI )8% to 32%).
Microbiological evaluation of MRSA isolates from each patient
revealed that all isolates were susceptible to vancomycin
(MICs £1 mg/L) [30]. Success rates for daptomycin vs.
vancomycin–gentamicin were, respectively, 45% and 27% in
complicated bacteraemia, 60% and 45% in uncomplicated
bacteraemia, and 50% and 50% in right-sided MRSA endocardi-
tis [29]. Neither daptomycin nor vancomycin–gentamicin ther-
apy was effective in left-sided MRSA native valve endocarditis,
and new approaches are urgently needed.
In Europe, daptomycin has been indicated for the treat-
ment of cSSTIs since 2006, and for the treatment of right-
sided endocarditis due to S. aureus and S. aureus bacteraemia
when associated with right-sided endocarditis or with cSSTI
since 2007. Worldwide, clinical experience with daptomycin
includes c. 640 000 patients, encompassing a range of patho-
gens and patient populations, who have been treated since
its launch in the USA in 2003 (Cubist Pharmaceuticals; http://
www.cubicin.com/). Results from the Cubicin Outcomes
Registry and Experience (CORE) post-marketing surveillance
programme indicate that daptomycin is both safe and effec-
tive for the treatment of Gram-positive infections [31,32].
Other key features of the ideal antibiotic are an ability to
resolve infections rapidly and a low risk of resistance devel-
opment. Daptomycin is rapidly bactericidal without causing
cell lysis [33], and this is thought to reduce the release of
bacterial proinﬂammatory mediators [34,35]. These features
are also thought to limit the potential for the development
of resistance or cross-resistance [36], and indeed very little
resistance has been reported in the 5 years that daptomycin
has been licensed.
The changing landscape of Gram-positive infections and
available antibiotic agents warrants a re-evaluation of thera-
peutic options for patients with Gram-positive infections. In
this supplement, J. Segreti illustrates the importance of appro-
priate initial antibiotic therapy for patient outcome, using case
studies, and G. Sakoulas examines the speciﬁc requirements
of different patient groups by highlighting informative data
from CORE. Looking ahead, E. Barton and A. MacGowan
examine the current and future antibiotic armamentarium,
assessing how these agents might be best employed
to improve patient outcomes in forthcoming years. Finally,
J.-P. Stahl outlines a four-point strategy for maximizing positive
outcomes overall. To ensure continued positive outcomes for
patients with Gram-positive infections, future treatment pro-
tocols and guidelines will need to collectively consider the
changing epidemiology of these infections, recent therapeutic
advances, and key insights from international experience.
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